In a filing, Syndax Pharmaceuticals Inc revealed its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported $0.11 million on May 16 ’25. In the deal valued at $8.99 per share,11,765 shares were bought. As a result of this transaction, Botwood Nicholas A.J. now holds 35,165 shares worth roughly $0.37 million.
Then, Huber Martin H. Jr. bought 5,000 shares, generating $44,950 in total proceeds. Upon buying the shares at $8.99, the Director now owns 79,000 shares.
Before that, Katkin Keith bought 10,000 shares. Syndax Pharmaceuticals Inc shares valued at $91,120 were divested by the Director at a price of $9.11 per share. As a result of the transaction, Katkin Keith now holds 100,000 shares, worth roughly $1.06 million.
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Tuesday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock jump 13.66% to $10.57. Over the last five days, the stock has gained 3.73%. Syndax Pharmaceuticals Inc shares have fallen nearly -20.05% since the year began. Nevertheless, the stocks have fallen -49.47% over the past one year. While a 52-week high of $25.07 was reached on 02/21/25, a 52-week low of $8.58 was recorded on 05/15/25. SMA at 50 days reached $12.08, while 200 days put it at $15.73.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 10.16, which if violated will result in even more drops to 9.76. On the upside, there is a resistance level at 10.84. A further resistance level may holdings at 11.11. The Relative Strength Index (RSI) on the 14-day chart is 45.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.56%. Stochastics %K at 18.82% indicates the stock is a buying.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
